drugset / Trial / NCT05164341
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.
Timeline
- Start
- 2021-12-17
- Primary completion
- 2026-07-21
- Completion
- 2026-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Metreleptin | Protein / enzyme biologic | — | Subcutaneous |